microbiologie médicale et infectiologie

19/10/2009

Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. (microbiologie médicale et infectiologie)

19/10/2009

LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. (microbiologie médicale et infectiologie)

19/10/2009

Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. (microbiologie médicale et infectiologie)

19/10/2009

Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors. (microbiologie médicale et infectiologie)

19/10/2009

Quorum-quenching acylase reduces the virulence of Pseudomonas aeruginosa in a Caenorhabditis elegans infection model. (microbiologie médicale et infectiologie)

19/10/2009

Combined inactivation of lon and ycgE decreases multidrug susceptibility by reducing the amount of OmpF porin in Escherichia coli. (microbiologie médicale et infectiologie)

19/10/2009

Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers. (microbiologie médicale et infectiologie)

19/10/2009

Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis. (microbiologie médicale et infectiologie)

19/10/2009

The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential. (microbiologie médicale et infectiologie)

19/10/2009

In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. (microbiologie médicale et infectiologie)